LMV-12 plus Osimertinib for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called LMV-12 combined with osimertinib for people with advanced non-small cell lung cancer that has certain genetic changes (MET amplification or RET fusion) and has stopped responding to standard EGFR inhibitor treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer that cannot be removed with surgery and has come back after prior treatment with an EGFR inhibitor (like erlotinib, gefitinib, or osimertinib).
- Your tumor must have either a MET amplification or a RET fusion, confirmed by a biopsy or blood test.
- You must be 18 years or older.
- You must have adequate blood counts (neutrophils, platelets, hemoglobin) and acceptable liver and kidney function.
- If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before starting treatment and use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new drug (BL-B01D1) combined with osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and who have not had any previous treatment. The goal is to see if the combination works better than standard care.
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
This trial tests combining an EGFR-targeted pill (like osimertinib) with the intravenous drug bevacizumab for people with advanced non-small cell lung cancer that has an EGFR mutation and has not been treated before. The goal is to see if this combination works better when guided by a special blood test that finds cancer cells.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.